If You Invested in Regencell Bioscience Holdings Ltd (RGC)

Regencell Bioscience Holdings Limited (NASDAQ: RGC) is an early-stage bioscience company that focuses on the research, development and commercialization of Traditional Chinese Medicine (TCM) for specific medical conditions. According to the company’s public disclosures and press releases, Regencell concentrates on neurocognitive disorders and degenerations, in particular attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), as well as infectious diseases that affect the immune system, including COVID-19.

The company commenced operations in Hong Kong in 2014 and is incorporated under the laws of the Cayman Islands. Its operations and research activities are closely tied to a strategic TCM research partner referred to as the “TCM Practitioner,” who developed proprietary formulae and a TCM brain theory known as the Sik-Kee Au TCM Brain Theory®. This theory underpins Regencell’s approach to treating neurological disorders and infectious diseases using natural, orally administered liquid TCM formulations.

Business focus and therapeutic areas

Regencell’s stated business focus is on TCM-based candidates for:

• Neurocognitive disorders and degenerations, specifically ADHD and ASD.
• Infectious diseases affecting the immune system, such as COVID-19.

The company reports having completed its first research study using personalized TCM formulae for the treatment of ADHD and ASD in Hong Kong. Building on this work, it aims to develop and commercialize three liquid-based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients, initially in Hong Kong and, as it deems appropriate, in other markets.

Traditional Chinese Medicine platform and formulae

Regencell’s TCM formulae candidates are derived from a TCM base formula and an adjustable formula developed by its strategic TCM partner over more than three decades of clinical practice. The company describes these candidates as natural, orally administered liquid formulae. For ADHD and ASD, Regencell has used both personalized and standardized formulae in research and efficacy trials.

The company has also developed an investigational oral TCM candidate for COVID-19, known as RGC-COV19TM (Regencell Bioscience (RGCA-CV01) liquid formulation). Regencell describes RGC-COV19TM as a natural, orally administered liquid formula that aims to reduce and eliminate mild to moderate COVID-19 symptoms within a defined treatment period, using what it characterizes as a holistic TCM approach.

ADHD and ASD research and efficacy trials

Regencell reports that it has conducted research studies and efficacy trials for ADHD and ASD using its TCM formulae in Hong Kong. Its first research study used personalized TCM formulae for ADHD and ASD treatment. Subsequently, the company initiated a second efficacy trial using standardized TCM formulae for children clinically diagnosed with ADHD and/or ASD.

In the second efficacy trial, Regencell used several assessment tools to evaluate changes in symptoms over a three-month treatment period, including:

• Sik-Kee Au TCM Brain Theory® Assessment for ADHD and ASD (SKATBT-A3), a 48‑item questionnaire developed by Regencell to assess overall physical and neurodevelopmental conditions.
• The Vanderbilt ADHD Diagnostic Parent Rating Scale (VADRS) for ADHD symptoms.
• The Autism Treatment Evaluation Checklist (ATEC) for ASD symptoms.

According to interim results disclosed by the company for the second efficacy trial using standardized formulae, Regencell reported mean percentage improvements in SKATBT-A3 scores and reductions in ADHD and ASD symptom scores over three months of treatment. The company also highlighted qualitative improvements such as better sleep quality, reduced temper, improved bowel movement and healthier complexion, as well as specific changes related to tongue control and flexibility, sociability and physical behavior. Regencell states that no adverse side effects were reported by patients in this trial.

COVID-19 program and EARTH efficacy trials

In addition to its ADHD and ASD work, Regencell has pursued an investigational TCM-based treatment for COVID-19. The company’s candidate, RGC-COV19TM (RGCA-CV01), has been evaluated in non-blinded efficacy trials collectively referred to as EARTH (Evaluation and Assessment of RGC-COV19TM TCM through a Holistic approach). These trials were conducted through Regencell Bioscience Asia Limited, a joint venture vehicle established to offer COVID-19 related treatments in certain regions.

The EARTH efficacy trial and an additional EARTH-B trial enrolled individuals with laboratory-confirmed SARS-CoV-2 infection and mild to moderate symptoms, with symptom onset within a specified number of days prior to treatment. Participants received RGC-COV19TM over a treatment period of up to six days. Regencell reports that a high proportion of enrolled patients experienced elimination of mild to moderate COVID-19 symptoms within the six-day treatment window, save for sensory dysfunction (loss or reduced sense of taste and smell) and occasional cough. The company also reports that many patients experienced elimination of one or more symptoms after one full dose of the investigational formula.

Regencell states that, based on self-reported data from participants, there were no unknown adverse side effects, no treatment-emergent adverse events, and no hospitalizations or deaths among trial participants during the reported periods. The company notes that these results have not yet been peer-reviewed and that RGC-COV19TM remains investigational.

Geographic footprint and joint venture activities

Regencell’s disclosures indicate that its research and clinical activities have involved multiple locations. For ADHD and ASD, its first research study using personalized TCM formulae was conducted in Hong Kong, and its second efficacy trial using standardized formulae enrolled children residing in Hong Kong.

For COVID-19, the company reports that its EARTH efficacy trial involved patients in Kuala Lumpur and Seremban in Malaysia, as well as in California in the United States. The additional EARTH-B trial was conducted in Malaysia. Regencell also describes earlier use of a proprietary TCM formula by its strategic partner to treat voluntary COVID-19 patients in the United States.

To expand access to its COVID-19 related treatments, Regencell formed a joint venture through its wholly owned Hong Kong subsidiary with Honor Epic Enterprises Limited. According to company announcements, this joint venture is intended to trade, manufacture, market and distribute TCM formulae products and support COVID-19 treatment using TCM in ASEAN countries, India, Japan, Australia and New Zealand.

Corporate and capital markets profile

Regencell Bioscience Holdings Limited is listed on the Nasdaq Capital Market under the ticker symbol RGC. The company has described itself in public communications as an early-stage bioscience company. It has also disclosed that its ordinary shares are included in the MSCI World Micro Cap Index, which captures micro-cap representation across developed markets.

Company announcements note that a significant portion of Regencell’s ordinary shares is held by its Chairman and Chief Executive Officer, who has reported open-market purchases of ordinary shares using personal funds, as reflected in Schedule 13D filings with the U.S. Securities and Exchange Commission. The company has also reported additional corporate governance developments, such as the appointment and resignation of independent directors and the composition of its board committees, through Form 6‑K filings.

Approach to TCM and brain theory

Regencell’s TCM-based approach is grounded in the Sik-Kee Au TCM Brain Theory®, which emphasizes the relationship between brain function, heart function, blood flow, the central nervous system, the endocrine system and the blood circulatory system. According to the company’s descriptions, the theory posits that reduced blood flow, blockages and damage to interconnected systems can disrupt hormone production and neurotransmitter transmission, contributing to abnormal social behaviors and neurocognitive symptoms associated with ADHD and ASD.

In the context of COVID-19, the company states that RGC-COV19TM is designed to strengthen heart function, increase blood flow and deliver more oxygen to the brain, with the goal of reducing blood clots and restoring brain functions. The company also describes mechanisms such as reducing mucus and phlegm in the upper respiratory system, dispelling exterior viral pathogens, clearing endogenous and liver heat, detoxifying the liver and improving body circulation as part of its TCM rationale.

Regulatory and development considerations

Regencell’s press releases include extensive forward‑looking statements and risk disclosures. The company highlights that its TCM formulae candidates, including those for ADHD, ASD and COVID-19, are subject to regulatory approval processes and that there is uncertainty regarding the timing and outcome of research, development and commercialization efforts. It notes potential challenges such as difficulties enrolling patients in studies, the possibility of undesirable side effects, and the risk that earlier study results may not predict future outcomes.

Regencell also emphasizes that its efficacy trials have been non-blinded and that some data are based on patient or caregiver reports. The company acknowledges that results have not yet been peer-reviewed and that its products remain investigational. These statements underscore the early-stage nature of the company and the inherent uncertainties in bioscience and TCM-based therapeutic development.

Position within medicinal and botanical manufacturing

Within the broader medicinal and botanical manufacturing industry, Regencell’s disclosures position it as a company focused on TCM-based liquid formulations rather than synthetic pharmaceuticals. Its activities span research, development and planned commercialization of formulae for clearly defined therapeutic areas—ADHD, ASD and infectious diseases affecting the immune system—using a framework grounded in a proprietary TCM brain theory and decades of practice by its strategic partner.

For investors and observers, Regencell’s profile combines elements of early-stage bioscience, traditional medicine, and emerging evidence from non-blinded efficacy trials. Its Nasdaq listing, inclusion in a micro-cap index, and ongoing SEC reporting provide a degree of transparency into its corporate developments, while its public communications outline its research focus and intended product candidates.